ONCE Is Hemorrhaging

We had some strong moves today in the biotechs. One stock in particular, ONCE, was down about -30% due to weaker performance of a hemophilia treatment it is developing. After the results were disclosed, shares proceeded to tumble. However, some analysts stated the decline is a buying opportunity, whereas others downgraded the stock. We also saw about roughly -10% move lower in PDCO, but there was no immediately clear reason for the decline. Here’s a recap of what happened.